Proactive Investors - Run By Investors For Investors

PureTech Health affiliate inks major deal with Japanese pharma

The partnership with Shionogi is worth US$20mln upfront and US$105mln in potential milestone payments
ADHD graphic
One of the drugs being developed is for attention deficit disorder

PureTech Health PLC (LON:PRTC) said its affiliate company has inked a major deal with a Japanese pharma worth US$20mln upfront and up to US$105mln in potential milestone payments.

The firm, Akili, is developing digital medicines AKL-T01 and AKL-T02.

The former is currently under review with the US Food and Drug Administration as a potential digital treatment for children with attention-deficit hyperactivity disorder, while the latter is in late-stage trials in children with an autism spectrum disorder.

The partnership with Shionogi & Co covers the markets of Japan and Korea.

View full PRTC profile View Profile

PureTech Health Timeline

January 22 2016

Related Articles

lung in x-ray
February 25 2019
The company has been developing a treatment for chronic lung disease in-house and has partnered with an Australian group to develop a drug for rare liver and lung complaints
June 27 2018
Lancor Scientific is aiming to carry out an initial coin offering by issuing Medici, a new currency based on Ethereum to help Tumour Trace to fund further development
Empty lab
September 19 2018
Management has made some tough decisions, cutting the cost base, since a disappointing first-half performance and expects the benefits to really kick in next year

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use